Prevalence of Antinuclear antibody positivity in Thai patients with Rheumatoid arthritis (Eng)
Main Article Content
บทคัดย่อ
Background: Antinuclear antibodies (ANA) are commonly detected in patients with rheumatoid arthritis (RA), although they are traditionally associated with other connective tissue diseases. The prevalence and clinical significance of ANA positivity in RA, particularly among Thai patients remain uncertain.
Objective: To investigate the prevalence of ANA positivity and its clinical associations in Thai patients diagnosed with RA.
Methods: A retrospective observational study was conducted at Thammasat University Hospital, including RA patients aged ≥18 years from 2014 to 2023. Data on demographics, laboratory parameters including ANA patterns, treatments, disease activity, complications and relapsed disease were collected. Patients were categorized based on ANA status, and comparisons were made between ANA-positive and ANA-negative groups.
Results: Among 118 RA patients, ANA positivity was identified in 88.1%. The most frequent ANA pattern was homogenous (50%), followed by fine speckled (34.62%). ANA-positive patients exhibited significantly higher C-reactive protein (CRP) levels (p = 0.002) and were higher prednisolone dosage (p < 0.001). Azathioprine and cyclosporineA usage was exclusive to ANA-positive individuals. No significant differences were observed in demographic characteristics, disease duration, disease activity, remission, relapsed, extra-articular manifestations, or adverse events. Data loss, particularly for ESR and CRP, was noted as a study limitation.
Conclusion: ANA positivity is highly prevalent among Thai RA patients and is associated with elevated inflammatory markers and increased immunosuppressive therapy. Further prospective studies are necessary to elucidate the prognostic role of ANA in RA and its potential impact on personalized treatment approaches.
Article Details

อนุญาตภายใต้เงื่อนไข Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
(ใส่ข้อความเดียวกันกับ ก๊อปปี้ไลน์ก็ได้)ดูตัวอย่างได้ที่หน้าบทความ---บทความนี้ตีพิมพ์เป็นลิขสิทธื์ของใคร...
เอกสารอ้างอิง
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-38.
McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011;365(23):2205-19.
Tan EM, Feltkamp TEW, Smolen JS, et al. Range of antinuclear antibodies in “healthy” individuals. Arthritis Rheum. 1997;40(9):1601-11.
Takei S, Ishigaki Y, Shimojima Y, et al. High frequency of antinuclear antibodies in patients with rheumatoid arthritis. Clin Rheumatol. 1990;9(4):501-5.
Suresh E. Diagnostic approach to patients with suspected systemic lupus erythematosus. Postgrad Med J. 2006;82(970):476-82.
Mosca M, Tani C, Carli L, Bombardieri S. Undifferentiated CTD: A wide spectrum of autoimmune diseases. Best Pract Res Clin Rheumatol. 2012;26(1):73-77.
Reksten TR, Berggreen E, Semb AG, et al. Serological and clinical features of ANA-positive patients with RA. Scand J Rheumatol. 2019;48(4):262-7.
Olsen NJ, Karp DR. Autoantibodies and SLE-like features in rheumatoid arthritis. Curr Rheumatol Rep. 2014;16(8):447.
Ramos-Casals M, Brito-Zerón P, Bombardieri S, et al. Drug-induced autoimmune diseases: Insights from the analysis of the Spanish Registry. Autoimmun Rev. 2010;9(8):493-7.
Centola M, Cavet G, Shen Y, et al. Development of a Multi-Biomarker Disease Activity Test for Rheumatoid Arthritis. PLoS One. 2013;8(4):e60635.
Yosmar R, Suija S, Srangenge Y, Almahdy A. Differences of Clinical Disease Activity Index (CDAI) in Rheumatoid Arthritis Patients Towards the Use of Disease Modifying Anti Rheumatic Drugs (DMARD). Adv Health Sci Res. 2021;40:125-9.
Paknikar SS, Crowson CS, Davis JM, Thanarajasingam U. Exploring the Role of Antinuclear Antibody Positivity in the Diagnosis, Treatment, and Health Outcomes of Patients With Rheumatoid Arthritis. ACR Open Rheumatol. 2021;3(6):422-6.
Pisetsky DS. Antinuclear antibodies in healthy individuals: The biology of autoantibodies. Nat Rev Rheumatol. 2017;13(6):349-57.
Chan EKL, Damoiseaux J, Carballo OG, et al. Report of the 15th International Workshop on Autoantibodies and Autoimmunity. Autoimmun Rev. 2019;18(7):673-85.